~~<i id='FFA8C86440'><strike id='FFA8C86440'><tt id='FFA8C86440'><pre id='FFA8C86440'></pre></tt></strike></i>~~

Home» focus» Wikipedia

Wikipedia

author：entertainment 2025-09-27 07:37:16 Page View：19931

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Gene therapy for Afghan refugees’ infant will be fully covered
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

explore

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Top private equity targets in 2023: cardiology, clinical trials, lasers

AdobeBysomemeasures,privateequityinvestmentlaggedin2023,ayearmarkedbygrowingdistressandhigh-profiled

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

Immune cells and nerve overgrowth may explain recurring UTI pain

AmastcellAdobeEachyear,morethan400millionurinarytractinfectionsoccurinpeoplearoundtheglobe.Andresear